{"nctId":"NCT02018627","briefTitle":"Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon","startDateStruct":{"date":"2014-04"},"conditions":["Type 1 Diabetes"],"count":20,"armGroups":[{"label":"Xeris glucagon","type":"EXPERIMENTAL","interventionNames":["Drug: Xeris glucagon"]},{"label":"Lilly glucagon","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lilly glucagon"]}],"interventions":[{"name":"Xeris glucagon","otherNames":[]},{"name":"Lilly glucagon","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 21 to 80 years old with type 1 diabetes for at least one year.\n* Diabetes managed using an insulin infusion pump using rapid-acting insulin such as insulin aspart (NovoLog), insulin lispro (Humalog), and insulin glulisine (Apidra) for at least one week prior to enrollment.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Unable to comply with study procedures.\n* Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the clamp study or the safety of the subject.\n* Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.\n* End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).\n* Hemoglobin \\< 11.5 gm/dl.\n* History of pheochromocytoma. Fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor (paroxysms of tachycardia, pallor, or headache; personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease; episodic or treatment of refractory hypertension, defined as requiring 4 or more medications to achieve normotension).\n* History of adverse reaction to glucagon (including allergy) besides nausea, vomiting, or headache.\n* Inadequate venous access as determined by study nurse or physician at time of screening.\n* Liver failure or cirrhosis.\n* Any other factors that, in the judgment of the principal investigator, would interfere with the safe completion of the study procedures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tmax","description":"tmax for Xeris vs. Lilly (non-inferiority)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"9.3"},{"groupId":"OG001","value":"15.7","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"AOCGIR","description":"Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"201.1","spread":"275.5"},{"groupId":"OG001","value":"132.2","spread":"87.9"}]}]}]},{"type":"SECONDARY","title":"GIRmin","description":"Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.2"},{"groupId":"OG001","value":"2.9","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"t½Max","description":"Glucagon t½max for Xeris vs. Lilly (non-inferiority)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"3.1"},{"groupId":"OG001","value":"5.9","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Injection Pain","description":"Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n\n-average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"17.7"},{"groupId":"OG001","value":"7.6","spread":"8.7"}]}]}]},{"type":"SECONDARY","title":"Injection Site Erythema","description":"Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n\n-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Maximal Nausea","description":"Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:\n\n-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Dermal Response (Draize Scale for Erythema and Eschar Formation)","description":"Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Dermal Response (Draize Scale Grade for Edema Formation)","description":"Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":[]}}}